[Development of beta 2-selective, long-acting agonists].
beta 2-Agonists have been the main bronchodilator drugs used in the symptomatic treatment of asthma. Regular use of beta 2-agonists, however, is well known to produce tolerance to their bronchoprotective effect. It has been pointed out that the over-treatment with beta 2-agonists may be associated with worsening asthma and increased risk of life-threatening attacks. To reduce the cardiovascular side effects, compounds with advanced beta 2-selectivity have been examined and established. Newly developed beta 2-selective agonists are structurally stable and long-acting. Some of them are reported to be effective for treatment of late asthmatic response, although conventional beta-agonists are thought to be relatively ineffective.
Inagaki
N
N
Department of Pharmacology, Gifu Pharmaceutical University.
Nagai
H
H
D000318:Adrenergic beta-Agonists / Q000009:adverse effects / Q000737:chemistry; D000818:Animals; D018926:Anti-Allergic Agents; D001249:Asthma / Q000188:drug therapy*; D003692:Delayed-Action Preparations; D015195:Drug Design; D004355:Drug Stability; D006801:Humans; D007073:Immunoglobulin E / Q000096:biosynthesis; D011943:Receptors, Adrenergic, beta / Q000378:metabolism / Q000502:physiology
D000318:Adrenergic beta-Agonists; D018926:Anti-Allergic Agents; D003692:Delayed-Action Preparations; D011943:Receptors, Adrenergic, beta; D007073:Immunoglobulin E